SYNACT PHARMA ApS: Financial statements 2020
CVR: 34459975
SYNACT PHARMA ApS (CVR 34459975) has filed annual accounts for 2020. In 2020, the company reported a gross profit of DKK -16,676,255 and a net result of DKK -14,002,315 compared with DKK -9,826,308 the year before. Equity amounted to DKK 11,357,224. The solvency ratio was 89.5%.
- Gross Profit
- -16,676,255 kr.
- Profit/Loss
- -14,002,315 kr.
- Equity
- 11,357,224 kr.
- Total Assets
- 12,691,131 kr.
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2020 | - | -16.7 mio. | -14 mio. | 11.4 mio. | - |
| 2019 | - | -11.5 mio. | -9.8 mio. | -21.8 mio. | - |
| 2018 | - | -16.8 mio. | -13.6 mio. | -12 mio. | - |
| 2017 | - | -10 mio. | -8.3 mio. | 1.6 mio. | - |
| 2016 | - | -9.9 mio. | -8.9 mio. | 9.9 mio. | - |
How creditworthy is SYNACT PHARMA ApS?
See the CDS score and get a full credit report with recommended credit limit and payment terms.
Read about the CDS scoreEvents in 2020
SYNACT PHARMA ApS has published its annual report for 2019. Gross profit came to DKK -11,468,376, and the net result was DKK -9,826,308.
About SYNACT PHARMA ApS
SYNACT PHARMA ApS is a Danish company of the type Anpartsselskab based in Holte, founded in 2012. The company is registered under the industry Fremstilling af farmaceutiske præparater. The company was previously named SYNACTION PHARMA ApS. The management consists of Jeppe Øvli Øvlesen, Thomas Boesen and Ann Kristin Brøgger Led. The company is owned by SynAct Pharma AB. In 2025, the company reported a gross profit of DKK -53,194,923 and a net result of DKK -59,812,937 compared with DKK -30,477,376 the year before. Equity amounted to DKK 20,295,649.
